Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of karenitecin in treating patients who have
persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer that has not
responded to platinum-based treatment. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die.